USSTOCK.TODAY
Weekend. Closed Log in Sign up

Mentari Therapeutics Inc(MTRI) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today

MTRI
MTRI
New
Mentari Therapeutics Inc
At close Nov 20 at 4:00 PM ET (Korea 11/21 06:00)
$14.70
-0.54 ▼ -3.57%
Nov 20 at 4:01 PM ET (Korea 11/21 06:01)
$14.48
-0.22 ▼ -1.50%
Broadening Resistance 19.93 Support 11.99 Holding

AI-drawn chart patterns are for reference only.

Full metrics table

Index ⓘ -P/E ⓘ -EPS (ttm) ⓘ -31.06Insider Own ⓘ -Shs Outstand ⓘ 52.8MPerf Week ⓘ -20.97%
Market Cap ⓘ 0.78BForward P/E ⓘ -EPS next Y ⓘ -Insider Trans ⓘ -Shs Float ⓘ 4.6MPerf Month ⓘ 10.53%
Enterprise Value ⓘ 0.78BPEG ⓘ -EPS next Q ⓘ -Inst Own ⓘ 12.56%Short Float ⓘ 0.14%Perf Quarter ⓘ 2.8%
Income ⓘ -0.01BP/S ⓘ 946.79EPS this Y ⓘ -Inst Trans ⓘ -Short Ratio ⓘ 0.35Perf Half Y ⓘ -14.53%
Sales ⓘ 0.00BP/B ⓘ -EPS next 5Y ⓘ -ROA ⓘ -158.97%Short Interest ⓘ 0.01MPerf YTD ⓘ 38.68%
Book/sh ⓘ -2.18P/C ⓘ 687.05EPS past 3/5Y ⓘ 63.64% 66.67%ROE ⓘ -224.38%52W High ⓘ -36.91% ($23.30)Perf Year ⓘ 17.6%
Cash/sh ⓘ 0.02P/FCF ⓘ -Sales past 3/5Y ⓘ -ROIC ⓘ -52W Low ⓘ 155.65% ($5.75)Perf 3Y ⓘ -81.85%
Dividend Est. ⓘ -EV/EBITDA ⓘ -EPS Y/Y TTM ⓘ 55.05%Gross Margin ⓘ -71.9%Volatility(W/M) ⓘ 15.74% 16.84%Perf 5Y ⓘ -99.84%
Dividend TTM ⓘ -EV/Sales ⓘ 945.41Sales Y/Y TTM ⓘ -82.91%Oper. Margin ⓘ -1238.62%ATR (14) ⓘ 2.26Perf 10Y ⓘ -99.94%
Dividend Ex-Date ⓘ -Quick Ratio ⓘ 0.5EPS Q/Q ⓘ 2.41%Profit Margin ⓘ -1657.72%RSI (14) ⓘ 47.11Recom ⓘ 1
Dividend Gr. 3/5Y ⓘ -Current Ratio ⓘ 0.5Sales Q/Q ⓘ -100%SMA20 ⓘ -8.91% ($16.14)Beta ⓘ 0.95Target Price ⓘ $33.75
Payout ⓘ -Debt/Eq ⓘ -Earnings ⓘ 2026/11/3SMA50 ⓘ 1.02% ($14.55)Rel Volume ⓘ 4.71Prev Close ⓘ $15.24
Employees ⓘ 6LT Debt/Eq ⓘ -EPS/Sales Surpr. ⓘ -SMA200 ⓘ 18.27% ($12.43)Avg Volume(3M) ⓘ 0.02MPrice ⓘ $14.7
IPO ⓘ 2008/11/17Option/Short ⓘ No/YesTrades ⓘ 558Volume ⓘ 85,157Change ⓘ -3.57%
Company
MTRI MTRIMentari Therapeutics Inc | NASD | Biotechnology

💊 A clinical-stage biotechnology company developing antibody therapies for migraine prevention. Following its merger with InMed Pharmaceuticals, it trades on the Nasdaq under the ticker $MTRI and is headquartered in Waltham, Massachusetts, USA. Its primary candidates include a monoclonal antibody targeting pituitary adenylate cyclase-activating polypeptide and a bispecific antibody targeting both that and calcitonin gene-related peptide.

Quote

Over the past 1 year, roughly in the middle

37% below its 1-year high.

Now $14.70
52w low$5.7552w high$23.30
52W Range51%
Volume ⓘ 85,157

Traded more than usual. That is 471% of its average volume.

D
Overall · many cautions
We judged 4 of the 8 questions below. 3 need caution.
No data for growth, earnings, outlook, dividends, or not applicable.
Peer comparison Biotechnology

It ranks #166 of 598 in the industry

Based on market cap of $776M.

FAQ

FAQ

MTRI belongs to the Healthcare sector and operates in the Biotechnology industry.

The market cap of MTRI is approximately $776M, ranking 2,684 within its sector.

MTRI has recorded a 52-week high of $23.30 and a low of $5.75.

Telegram KakaoTalk
Briefs · earnings · signals, first Telegram · KakaoTalk channels